Medarex

New developments from Medarex highlighted recently

Published in Health Business Week, February 2nd, 2007

New developments from Medarex highlighted recently.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Medarex.

Report 1: Medarex, Inc. (MEDX) and PharmAthene, Inc., a privately held biotechnology company focused on the development of biodefense countermeasures, announced positive phase 1 study results for Valortim (MDX-1303) in healthy volunteers.

Valortim is a fully human antibody against anthrax infection developed using Medarex's UltiMAb human antibody development system. The study results were presented in October 2006 at the Infectious Diseases Society of America (IDSA)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-02-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry